Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows

Host: Marlene Mimi Maeusli, PhD. This is a non-certified educational series produced and controlled by ReachMD. As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world findings on post-infusion monitoring for idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), which were presented at the International Myeloma Society Annual Meeting in September 2025.